AOD-9604 vs Semaglutide
Independent, side-by-side comparison of AOD-9604 and Semaglutide: mechanism, half-life, dose range, safety profile, and live vendor pricing. Updated continuously as new research and listings land.
Live price snapshot
AOD-9604
Semaglutide
AOD-9604
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino-acid peptide fragment of human growth hormone (hGH) corresponding to residues 177-191 of the hGH molecule plus a tyrosine addition at the N-terminus (sequence:…
Live lowest price: $34.99 across 3 vendors
Full AOD-9604 profileSemaglutide
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with a molecular weight of 4113.58 Da and CAS number 910463-68-2. It is a 31-amino-acid peptide analog of human GLP-1(7-37) with two key structural…
Live lowest price: $39.00 across 12 vendors
Full Semaglutide profileSide-by-side comparison
| Attribute | AOD-9604 | Semaglutide |
|---|---|---|
| Category | Metabolic & Weight Loss | Metabolic & Weight Loss |
| Research Stage | Phase II | FDA Approved |
| Mechanism of Action | AOD-9604's claimed mechanism is lipolysis (fat breakdown) via a C-terminal hGH-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the mechanistic details remain incompletely characterized and contested. The "Lipolytic… | GLP-1 Receptor Agonism and cAMP Signaling Semaglutide binds to the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed on pancreatic beta cells, hypothalamic neurons, gastric smooth muscle, cardiac myocytes, and other tissues. Upon binding,… |
| Half-Life | ~30–60 minutes | ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification |
| Typical Dose Range | 250–600 mcg per injection | Diabetes (Ozempic): 250-1000 mcg weekly; Weight management (Wegovy): 2400 mcg weekly (after 16-week titration); Oral (Rybelsus): 3-14 mg daily |
| Dosing Frequency | Once daily, typically morning fasted | Once weekly subcutaneous injection |
| Administration | Subcutaneous, Oral | Subcutaneous (weekly), Oral (daily) |
| Side Effects | AOD-9604's side effect profile is largely benign based on clinical trial data, reflecting its failure to produce significant physiological effects — a drug that does little tends to cause few side effects. From Phase 2B Clinical Trial (Heffernan 2008): In the… | Nausea (especially at initiation — dose-dependent), vomiting, diarrhea, constipation, abdominal pain, decreased appetite (therapeutic effect), headache, fatigue, dizziness. Rare: pancreatitis, gallbladder issues, thyroid C-cell tumors (rodent studies).… |
| Molecular Weight | 1817.1 Da | 4113.6 Da |
| Common Vial Sizes | 2mg, 5mg | 3mg, 5mg, 10mg |
Price History
4 data points- Unknown
- Nova Peptides
- VANDL Labs
- Ion Peptide
Price History
5 data points- OF
- Nova Peptides
- VANDL Labs
- LB
- Ion Peptide
AOD-9604 — potential benefits
- Fat loss
- Metabolic improvement
- Joint repair (proposed)
- No insulin resistance
- No IGF-1 effects
Semaglutide — potential benefits
- Mean body weight reduction of 14.9% at 68 weeks in STEP 1 trial (PMID: 33567185)
- Sustained weight loss of ~15% maintained through 104 weeks in STEP 5 (PMID: 34170647)
- 20% reduction in major adverse cardiovascular events in SELECT trial (PMID: 37351564)
- HbA1c reduction of 1.5-1.8% in type 2 diabetes
- Reduction in systemic inflammation (hs-CRP reduced ~37% in SELECT)
- Available in both subcutaneous (weekly) and oral (daily) formulations
- Improved cardiometabolic risk factors including blood pressure and lipid profile
Frequently asked
What's the difference between AOD-9604 and Semaglutide?
AOD-9604 is a metabolic & weight loss that aod-9604's claimed mechanism is lipolysis (fat breakdown) via a c-terminal hgh-fragment-specific pathway distinct from classical growth hormone receptor signaling, though the…. Semaglutide is a metabolic & weight loss that glp-1 receptor agonism and camp signaling semaglutide binds to the glp-1 receptor (glp-1r), a class b g-protein coupled receptor expressed on pancreatic beta cells, hypothalamic…. The two differ in mechanism, half-life (~30–60 minutes vs ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification), and typical dose range.
Which has the longer half-life, AOD-9604 or Semaglutide?
AOD-9604 has a half-life of ~30–60 minutes. Semaglutide has a half-life of ~7 days (168 hours), enabled by C18 fatty diacid albumin-binding modification. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, AOD-9604 or Semaglutide?
Current lowest live price on BodyHackGuide: AOD-9604 from $34.99, Semaglutide from $39.00. Prices are pulled from the vendor listings tracked on BHG and change frequently — see the compare tables on each compound page for the current set of offers.
Can you stack AOD-9604 and Semaglutide?
Stacking depends on mechanism overlap, safety profile, and goals. AOD-9604 and Semaglutide should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Live listings from the vendors we track, refreshed continuously.
Related comparisons
Research use only. BodyHackGuide is an independent research reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks — this never affects the data or pricing shown. See editorial standards and affiliate disclosure.